Systems Biology Ireland

ucd.ie

SBI established in 2009 under the Science Foundation Ireland CSET programme has successfully developed an integrated mathematical modelling and experimental research programme focusing on the design of new therapeutic approaches to cancer, degenerative and inflammatory diseases based on a systems level, mechanistic understanding of cellular signal transduction networks. SBI is one of the few centres in Europe with the necessary in house expertise, technologies and capabilities to apply systems biology approaches to mammalian models. It’s recognition internationally within the field of systems biology led to the Centre’s invited participation in three large European funded consortia initiatives in 2012 namely the ITFoM, CASyM and ISBE, the last of which is included on the ESFRI 2010 Roadmap.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

HARBOUR BIOMED ANNOUNCES APPROVAL FOR PHASE I TRIAL OF B7H4X4-1BB BISPECIFIC ANTIBODY IN AUSTRALIA

Harbour BioMed | February 28, 2022

news image

Harbour BioMed announced that, it has been approved by the Institutional Review Boards to commence phase I trial of its B7H4x4-1BB bispecific antibody in Australia. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of HBM7008 in patients with solid tumors. HBM7008 is generated from our unique and innovative HBICE® platform. It targets Tumor Associated Antigen mediated crosslinking T cell activation t...

Read More

Industrial Impact

NEXEO PLASTICS AND EARTH RENEWABLE TECHNOLOGIES SIGN AGREEMENT TO DISTRIBUTE BIOCOMPOUNDS IN NORTH AMERICA

Nexeo Plastics | March 02, 2022

news image

Nexeo Plastics, a leading global thermoplastics resin distributor, has announced an agreement with Earth Renewable Technologies, Inc. (ERT), a biotechnology company, to distribute ERT’s BioCompounds in Canada and the United States. “We are extremely pleased to collaborate with ERT to increase the slate of sustainable products we offer our customers. ERT’s BioCompounds complement the products we already carry and help us close the gap in our ...

Read More

CORTEXYME SUCCESSFULLY COMPLETES ACQUISITION OF NOVOSTEO

Cortexyme | May 21, 2022

news image

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Novosteo stockholders now own approximately 15.5% of the combined company. With the completion of the acquisition, Cort...

Read More

Industry Outlook

BIOMEDICAN ENTERS THE ASTAXANTHIN MARKET THROUGH BIOSYNTHESIS PLATFORM TO TARGET HIGH-VALUE COMPOUND AND DISRUPT THE CURRENT TECHNOLOGIES

BIOMEDICAN | December 03, 2020

news image

BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances. Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Ast...

Read More
news image

Industrial Impact

HARBOUR BIOMED ANNOUNCES APPROVAL FOR PHASE I TRIAL OF B7H4X4-1BB BISPECIFIC ANTIBODY IN AUSTRALIA

Harbour BioMed | February 28, 2022

Harbour BioMed announced that, it has been approved by the Institutional Review Boards to commence phase I trial of its B7H4x4-1BB bispecific antibody in Australia. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of HBM7008 in patients with solid tumors. HBM7008 is generated from our unique and innovative HBICE® platform. It targets Tumor Associated Antigen mediated crosslinking T cell activation t...

Read More
news image

Industrial Impact

NEXEO PLASTICS AND EARTH RENEWABLE TECHNOLOGIES SIGN AGREEMENT TO DISTRIBUTE BIOCOMPOUNDS IN NORTH AMERICA

Nexeo Plastics | March 02, 2022

Nexeo Plastics, a leading global thermoplastics resin distributor, has announced an agreement with Earth Renewable Technologies, Inc. (ERT), a biotechnology company, to distribute ERT’s BioCompounds in Canada and the United States. “We are extremely pleased to collaborate with ERT to increase the slate of sustainable products we offer our customers. ERT’s BioCompounds complement the products we already carry and help us close the gap in our ...

Read More
news image

CORTEXYME SUCCESSFULLY COMPLETES ACQUISITION OF NOVOSTEO

Cortexyme | May 21, 2022

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Novosteo stockholders now own approximately 15.5% of the combined company. With the completion of the acquisition, Cort...

Read More
news image

Industry Outlook

BIOMEDICAN ENTERS THE ASTAXANTHIN MARKET THROUGH BIOSYNTHESIS PLATFORM TO TARGET HIGH-VALUE COMPOUND AND DISRUPT THE CURRENT TECHNOLOGIES

BIOMEDICAN | December 03, 2020

BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances. Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Ast...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us